Last reviewed · How we verify
NCT03438968
Women in Cardiac Rehabilitation: Optimizing the Training Response
NA trial testing Exercise training in Exercise Training in 40 participants. Status unknown.
31 December 2018
Quick facts
| Lead sponsor | University of Vermont |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 24 August 2017 |
| Primary completion | 31 December 2018 |
| Estimated completion | 30 April 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Exercise training
Conditions studied
- Exercise Training — all drugs for Exercise Training →
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
- Women — all drugs for Women →
- Cardiac Rehabilitation — all drugs for Cardiac Rehabilitation →
Sponsor
University of Vermont
Who can join
18 and older, female only, with Exercise Training or Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cardiovascular disease (CVD) is highly prevalent in women resulting in 398,086 deaths annually. Even as women participate in traditional CR programs, data specificity and subsequent research have yet to emerge in a meaningful way so that women-centered CR can be better customized and their outcomes properly assessed. Aerobic fitness is a powerful predictor of prognosis in individuals with CVD yet there is evidence that women do not improve their peak VO2 as much as men during CR. We have designed a training program for women based upon past research with a goal of optimizing their training potential in CR. This program combines the utilization of a training technique termed high intensity interval training along with specific strength training exercises of the upper legs. We hypothesize that women, irrespective of age, would be capable of high intensity interval training to improve peak aerobic capacity in the CR setting. Furthermore, since women often have a deficit of thigh strength entering CR, and thigh strength correlates with endurance walking,strength training will also be included. The purpose of this study is to examine the value of high intensity interval training and strength training to maximize aerobic training response in CR for women. This may contribute to establishing specific protocols and training guidelines for future program design for women in CR. Since a set of comprehensive CR guidelines pertaining to women is lacking, it is hoped that the results of this study will help us develop exercise protocols and regimen to better structure and modulate CR programs for optimal benefit to women.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Optimizing Training Response for Women in Cardiac Rehabilitation: A Randomized Clinical Trial.
Khadanga S, Savage PD, Pecha A, Rengo J, et al · · 2022 · cited 24× · PMID 34817540 · DOI 10.1001/jamacardio.2021.4822
Verify or expand the search:
- PubMed search for NCT03438968
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Exercise training
Trials testing the same drug.
- NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
- NCT07513987 — IMPACT: Immune and Musculoskeletal Physiological Adaptations to Combined Exercise Training & Nutrition · NA · not yet recruiting
- NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting
- NCT07341711 — Long-term Adaptations of Skeletal Muscle After Hybrid Training. · NA · not yet recruiting
- NCT07300332 — Exercise Training and Vitamin D Metabolism · NA · recruiting
Other recruiting trials for Exercise Training
Currently open trials in the same condition.
- NCT07322939 — Effects of Exercise With Visual Feedback in Parkinson's Disease · NA · recruiting
- NCT07164911 — Predictive Factors of Response to Phase II Cardiac Rehabilitation in Heart Failure With Reduced Ejection Fraction · recruiting
- NCT07216755 — Effects of Breathing Training and Nitrate on Exercise at Simulated Altitude · NA · recruiting
- NCT07128030 — Moderate-Intensity Exercise and Pain Sensitization in Breast Cancer Survivors: A Case-Based Study · NA · recruiting
- NCT06453473 — Transfer Effects of Stationary Bicycle Perturbation Training on Older Adults' Cycling Skills · NA · recruiting
Other University of Vermont trials
Trials by the same sponsor.
- NCT07495098 — Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer · Phase 1 · not yet recruiting
- NCT07440641 — RE-FIT (Remote Exercise for Physical Function in WTC Responders With Prostate Cancer) · NA · not yet recruiting
- NCT06993129 — A Multi-Site Hybrid Type I Effectiveness-Implementation Randomized Trial of an Emergency Care Action Plan for Infants Wi · NA · not yet recruiting
- NCT07383727 — Readiness to Change and the Implementation of Home Modifications for Adults Over 60 · NA · not yet recruiting
- NCT06670079 — Prolonged Exposure Therapy to Treat Posttraumatic Stress Disorder in Pregnant Patients · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03438968 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Vermont
- Last refreshed: 20 February 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03438968.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing